"As we’ve previously indicated, with respect to the ViraDx and FebriDx sales outlook, we anticipate FY25 sales for both products to be up materially on what was achieved in FY24." Would we believe the "anticipated increase", given comments about "robust sales" amounted to $300,000?
Seems like their reply to FMB answered this already? As Surandy commented, they don't individually breakdown the sales for each product and any increase in sales I could probably guarantee is in increase to Viradx.
We can only hope their expectations match ours.
Add to My Watchlist
What is My Watchlist?
